“Nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are still asked to provide it.”

The co-founders of Darwin Health write that the real work for making dramatic gains against pancreatic cancers is just beginning.

China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.

RFK Jr. had long signaled that he was going to do something big on peptides. Now the moment has arrived.

Those calling for Trump’s removal under the 25th Amendment are misguided. Here’s why, writes Lawrence K. Altman.

"Instead of organizing health data around institutions, we might organize it around individuals," write Meta's Freddy Abnousi and Stanford's Celina Yong.

Who would want to be the head of the FDA's Center for Biologics Evaluation and Research?

Like it or not, PBMs are fiduciaries.

Congress must pass bipartisan legislation to ensure Medicare coverage of breakthrough medical technologies, writes a physician and inventor.

“To critics of Medicare Advantage, these results scramble the debate,” writes Optum CMO Ken Cohen.

Doctors working with patients with Alzheimer’s and other causes of dementia must ask: Who will take part in your care?